Bio

Danielle Polevoi is a recently board certified physician assistant who graduated from Stanford University School of Medicine’s Master of Science in Physician Assistant Studies program with a concentration in Medical Education. During PA school, she was selected as one of fifteen students nationwide to participate in The PAEA’s Future Educator Fellowship program. She was also chosen by Stanford MSPA faculty as one of three students in the Class of 2022 to represent our program in the AAPA Virtual Challenge Bowl in 2021.

Prior to getting her master's degree, Danielle attended UCLA where she received a B.S. in Biology. In order to gain patient care experience for PA school, she worked as an Emergency Department Scribe at Zuckerberg San Francisco General Hospital and Trauma Center and as a medical assistant in a gynecologic surgery group.

Danielle was born and raised in San Francisco. She is eager to begin her career at SHC in the Medical ICU taking care of critically ill patients.

Clinical Focus

  • Physician Assistant
  • Medical ICU

Professional Education

  • Board Certification: National Commission on Certification of Physician Assistants, Physician Assistant (2022)
  • MSPA, Stanford School of Medicine, Physician Assistant Studies (2022)
  • BS, University of California, Los Angeles, Biology (2017)

Contact

  • Work
    University - Staff Department: Physician Assistant Studies Position: Instructional Faculty
    University - Affiliate Department: Physician Assistant Studies

Additional Info

  • Mail Code: 5237

All Publications

  • Antimicrobial peptides and the gut microbiome in inflammatory bowel disease. World journal of gastroenterology Gubatan, J., Holman, D. R., Puntasecca, C. J., Polevoi, D., Rubin, S. J., Rogalla, S. 2021; 27 (43): 7402-7422

    Abstract

    Antimicrobial peptides (AMP) are highly diverse and dynamic molecules that are expressed by specific intestinal epithelial cells, Paneth cells, as well as immune cells in the gastrointestinal (GI) tract. They play critical roles in maintaining tolerance to gut microbiota and protecting against enteric infections. Given that disruptions in tolerance to commensal microbiota and loss of barrier function play major roles in the pathogenesis of inflammatory bowel disease (IBD) and converge on the function of AMP, the significance of AMP as potential biomarkers and novel therapeutic targets in IBD have been increasingly recognized in recent years. In this frontier article, we discuss the function and mechanisms of AMP in the GI tract, examine the interaction of AMP with the gut microbiome, explore the role of AMP in the pathogenesis of IBD, and review translational applications of AMP in patients with IBD.

    View details for DOI 10.3748/wjg.v27.i43.7402

    View details for PubMedID 34887639

    View details for PubMedCentralID PMC8613745

  • Extubation to high-flow nasal cannula in critically ill surgical patients. The Journal of surgical research Dhillon, N. K., Smith, E. J., Ko, A., Harada, M. Y., Polevoi, D., Liang, R., Barmparas, G., Ley, E. J. 2017; 217: 258-264

    Abstract

    High-flow nasal cannula (HFNC) is increasingly used to reduce reintubations in patients with respiratory failure. Benefits include providing positive end expiratory pressure, reducing anatomical dead space, and decreasing work of breathing. We sought to compare outcomes of critically ill surgical patients extubated to HFNC versus conventional therapy.A retrospective review was conducted in the surgical intensive care unit of an academic center during August 2015 to February 2016. Data including demographics, ventilator days, oxygen therapy after extubation, reintubation rates, surgical intensive care unit and hospital length of stay, and mortality were collected. Self and palliative extubations were excluded. Characteristics and outcomes, with the primary outcome being reintubation, were compared between those extubated to HFNC versus cool mist/nasal cannula (CM/NC).Of the 184 patients analyzed, 46 were extubated to HFNC and 138 to CM/NC. Mean age and days on ventilation before extubation were 57.8 years and 4.3 days, respectively. Both cohorts were similar in age, sex, and had a similar prevalence of cardiopulmonary diagnoses at admission. Although prior to extubation HFNC had lengthier ventilation requirements (7.1 versus 3.4 days, P < 0.01) and ICU stays (7.8 versus 4.1 days, P < 0.01), the rate of reintubation was similar to CM/NC (6.5% versus 13.8%, P = 0.19). Multivariable analysis demonstrated HFNC to be associated with a lower risk of reintubation (adjusted odds ratio = 0.15, P = 0.02). Mortality rates were similar.Ventilated patients at risk for recurrent respiratory failure have reduced reintubation rates when extubated to HFNC. Patients with prolonged intubation or those with high-risk comorbidities may benefit from extubation to HFNC.

    View details for DOI 10.1016/j.jss.2017.06.026

    View details for PubMedID 28711371